These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 9648592

  • 1. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
    Markman M, Blessing JA, Moore D, Ball H, Lentz SS.
    Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
    Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS.
    Gynecol Oncol; 2001 Aug; 82(2):317-22. PubMed ID: 11531286
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Aug; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 6. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT.
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [Abstract] [Full Text] [Related]

  • 7. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [Abstract] [Full Text] [Related]

  • 8. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 9. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Sep; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
    Sørensen P, Høyer M, Jakobsen A, Malmström H, Havsteen H, Bertelsen K.
    Gynecol Oncol; 2001 Apr; 81(1):58-62. PubMed ID: 11277650
    [Abstract] [Full Text] [Related]

  • 11. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
    Gershanovich ML, Livshits ME, Antipenkova VI.
    Vopr Onkol; 2000 Apr; 46(5):604-7. PubMed ID: 11202196
    [Abstract] [Full Text] [Related]

  • 12. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A, Blessing J, Bender D, Mannel R, Morgan M, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [Abstract] [Full Text] [Related]

  • 13. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT.
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [Abstract] [Full Text] [Related]

  • 15. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
    Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog TJ, Rose PG.
    Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
    Gynecologic Oncology GroupUniversity of Texas, M.D. Anderson, 1515 Holcombe Blvd., Mail Box 121, Houston, TX 77030-4009, USA. MMarkman@mdanderson.org, Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S.
    Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
    [Abstract] [Full Text] [Related]

  • 17. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
    Moore DH, Valea F, Crumpler LS, Fowler WC.
    Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D.
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [Abstract] [Full Text] [Related]

  • 19. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Rose PG, Blessing JA, Arseneau J.
    Gynecol Oncol; 1996 Jul; 62(1):100-2. PubMed ID: 8690279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.